Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307527 | 0.88 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL4307130 | 0.87 | SLC6A2 (0.58) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL4311464 | 0.87 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL4310455 | 0.85 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL4311545 | 0.85 | TACR1 (0.53) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL4307795 | 0.82 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3TACR1HTR6 | |
| SCHEMBL4313433 | 0.80 | SLC6A2 (0.61) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL4309344 | 0.80 | SLC6A2 (0.61) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL4313693 | 0.80 | SLC6A2 (0.56) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL4312492 | 0.80 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488741-B2 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB PHARMA, S.A. (BE) | 2009-02-10 | — | — | US | disclosed |
| EP-1693061-A1 | Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases | UCB, S.A. (BE) | 2006-08-23 | — | — | EP | disclosed |
| EP-1556045-B1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB SA (BE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB, S.A. (BE) | 2006-06-15 | — | — | US | disclosed |
| EP-1556045-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004030668-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | PNMT, HTR5A, HTR4 | SLC6A4 50/4885SLC6A2 112/4885SLC6A3 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.